Precigen Reports Unregistered Equity Sales
Ticker: PGEN · Form: 8-K · Filed: Sep 17, 2025 · CIK: 1356090
| Field | Detail |
|---|---|
| Company | Precigen, Inc. (PGEN) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $79,000,000, $1,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, unregistered-securities
TL;DR
Precigen sold unregistered stock, potentially diluting existing shares.
AI Summary
Precigen, Inc. filed an 8-K on September 17, 2025, reporting unregistered sales of equity securities as of September 15, 2025. The filing does not specify the exact number of shares sold or the price per share, but it indicates a transaction occurred under the company's charter in Virginia.
Why It Matters
This filing indicates Precigen has issued equity securities without a prior public registration, which could impact existing shareholders through dilution or signal a need for capital.
Risk Assessment
Risk Level: medium — Unregistered sales can sometimes signal financial distress or lead to dilution for existing shareholders.
Key Players & Entities
- Precigen, Inc. (company) — Registrant
- Virginia (jurisdiction) — State of incorporation
- September 15, 2025 (date) — Date of earliest event reported
- September 17, 2025 (date) — Date of report
FAQ
What type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the exact type of securities.
How many shares were sold in this unregistered offering?
The filing does not disclose the number of shares sold.
What was the price per share for these unregistered securities?
The filing does not provide the price per share for the unregistered equity securities.
Under what exemption from registration were these securities sold?
The filing indicates 'Unregistered Sales of Equity Securities' but does not explicitly state the exemption from registration relied upon.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated September 15, 2025.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-09-17 16:58:44
Key Financial Figures
- $79,000,000 — tock (with an aggregate stated value of $79,000,000) into 54,937,411 shares of common stock
- $1,000 — 695.4103 shares of our common stock per $1,000 of stated value of Preferred Stock. Th
Filing Documents
- dp234458_8k.htm (8-K) — 20KB
- 0000950103-25-011775.txt ( ) — 178KB
- pgen-20250915.xsd (EX-101.SCH) — 3KB
- pgen-20250915_lab.xml (EX-101.LAB) — 33KB
- pgen-20250915_pre.xml (EX-101.PRE) — 22KB
- dp234458_8k_htm.xml (XML) — 3KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2025 Precigen, Inc. (Exact name of registrant as specified in its charter) Virginia 001-36042 26-0084895 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 20374 Seneca Meadows Parkway , Germantown , Maryland 20876 (Address of principal executive offices) (Zip Code) ( 301 ) 556-9900 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, No Par Value PGEN Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act Item 3.02. Unregistered Sales of Equity Securities. On September 15, 2025, the holders of Precigen, Inc.'s (the "Company's" and "our") 8.00% Series A Convertible Perpetual Preferred Stock ("Preferred Stock") converted 79,000 shares of Preferred Stock (with an aggregate stated value of $79,000,000) into 54,937,411 shares of common stock of the Company, which were delivered to such holders on September 17, 2025 pursuant to the terms of our Amended and Restated Articles of Incorporation and such Preferred Stock at the current conversion rate of 695.4103 shares of our common stock per $1,000 of stated value of Preferred Stock. The shares of our common stock issued upon conversion of the Preferred Stock were issued in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended, as involving an exchange by us exclusively with our existing security holders in a transaction where no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Precigen, Inc. By: /s/ Donald P. Lehr Donald P. Lehr Chief Legal Officer Dated: September 17, 2025